SARS-CoV-2 Vaccine Response in Patients with Muscle Disorders
Author Information
Author(s): Naka Tomoaki, Funato Michinori, Yasuda Kunihiko, Nakayama Takahiro, Kuru Satoshi
Primary Institution: NHO Nagara Medical Center, Gifu, Japan
Hypothesis
The study aimed to clarify the mechanism of the low immunogenicity of intramuscular SARS-CoV-2 mRNA vaccination in patients with muscular disorders.
Conclusion
The low immunogenicity of intramuscular SARS-CoV-2 mRNA vaccination against muscular disorders may be mainly affected by disease type and pathogenesis.
Supporting Evidence
- Patients with muscular disorders showed a lower tendency of antibody response compared to those without.
- Mean CT values were correlated with the antibody response in patients with muscular disorders.
- The study suggests that muscle quality may affect vaccine immunogenicity.
Takeaway
This study looked at how well the COVID-19 vaccine works in people with muscle problems, finding that their response is often weaker.
Methodology
The study evaluated 44 individuals, including 23 patients with muscular disorders and 21 without, measuring antibody levels and CT values of the deltoid muscle.
Potential Biases
Potential bias due to the small sample size and the retrospective nature of the study.
Limitations
The study size was small, and no significant differences were confirmed.
Participant Demographics
The median age of participants was 39 years, with 18 females (40.9%) and 26 males (59.1%).
Statistical Information
P-Value
0.07
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website